Open Access99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
Author(s) -
Paolo Rai,
Antonella De Palma,
Francesco Sudati,
Valentina Roffia,
Valentina Rigamonti,
Lucia Salvioni,
Miriam Colombo,
Marilena Ripamonti,
Antonello E. Spinelli,
Davide Mazza,
Pierluigi Mauri,
Rosa María Moresco,
Davide Prosperi,
Sara Belloli
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s276033
Subject(s) - ex vivo , in vivo , nanocarriers , biodistribution , doxorubicin , chemistry , drug delivery , materials science , pharmacology , cancer research , in vitro , medicine , nanotechnology , chemotherapy , biology , biochemistry , microbiology and biotechnology
The overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is usually associated with aggressive and infiltrating breast cancer (BC) phenotype, and metastases. Functionalized silica-based nanocarriers (SiNPs) can be labeled for in vivo imaging applications and loaded with chemotherapy drugs, making possible the simultaneous noninvasive diagnosis and treatment (theranostic) for HER2-positive BC.